February 18, 2015 -- Nuance Biotech, a Shanghai-based startup, has developed an unusual business model. As Mark Lotter, the company’s founder and CEO, told ChinaBio® Today in an exclusive interview, Nuance plans to in-license and develop drugs in both China and South Africa. The countries are similar in many ways, explains Lotter, but South Africa’s population is more diverse, which offers unique opportunities. Nuance will in-license drugs in all stages of development, from market-ready to pre-clinical. The company, which will soon begin fund raising, will attend the April ChinaBio® Partnership Forum in Shanghai to make its story better known.
Help employers find you! Check out all the jobs and post your resume.
